Composition of Huhtamaki’s Shareholders’ Nomination Board
HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 2.10.2020 AT 10:45
Composition of Huhtamaki’s Shareholders’ Nomination Board
Huhtamäki Oyj’s Annual General Meeting, held on April 29, 2020, resolved to establish a Shareholders’ Nomination Board and to adopt the Charter of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is responsible for preparing proposals to the Annual General Meeting, and, if necessary, to an Extraordinary General Meeting, for the election and remuneration of the members of the Board of Directors.
Each of the four largest shareholders of the Company have a right to appoint one member to the Nomination Board. In addition, the Chairman of the Board of Directors of the Company shall serve as an expert member of the Nomination Board. The shareholders entitled to appoint a member are determined annually on the basis of the shareholders’ register of the Company maintained by Euroclear Finland Ltd. on August 31.
The following composition of Huhtamaki’s Shareholders’ Nomination Board has been confirmed:
- Antti Arjava, Secretary General, The Finnish Cultural Foundation (Chairman)
- Annika Ekman, Head of Direct Equity Investments, Ilmarinen Mutual Pension Insurance Company
- Risto Murto, President and CEO, Varma Mutual Pension Insurance Company
- Johan Ståhl, Portfolio Manager, Lannebo Fonder
- Pekka Ala-Pietilä, Chairman of the Board of Directors of Huhtamaki (Expert member)
For further information, please contact:
Sami Pauni, Executive Vice President, Corporate Affairs and Legal, Group General Counsel, tel. +358 (0)10 686 7872
Huhtamaki is a key global player in sustainable food-on-the-go and food-on-the shelf packaging solutions. Our innovative products help billions of consumers around the world make responsible lifestyle choices every day. Today, packaging plays a significant role in food safety and convenience. We are committed to making packaging more circular and we embed sustainability in everything we do. We are focused on achieving carbon neutral production and having all our products designed to be recyclable, compostable or reusable by 2030.
With 100 years of history and a strong Nordic heritage we operate in 35 countries and 81 sites around the world. Our 18,800 employees are working to deliver smart next generation packaging. Our 2019 net sales totaled EUR 3.4 billion. Huhtamaki Group has its head office in Espoo, Finland and the parent company Huhtamäki Oyj is listed on Nasdaq Helsinki Ltd. Find out more about our Sustainability Action Plan and our ambition at www.huhtamaki.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Galapagos increases share capital through subscription right exercises4.12.2020 22:01:00 CET | Press release
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capital increase (including issuance premium) of €2,615,857.50. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,819,443.97, the total number of securities conferring voting rights amounts to 65,411,767, which is also the total
REC Silicon - Approval and publication of prospectus4.12.2020 20:39:33 CET | Press release
Lysaker, 4 December 2020. Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement"). A prospectus for listing of the 92,592,592 new shares in the Company issued in connection with the Private Placement was approved by the Financial Supervisory Authority of Norway on 4 December 2020. The prospectus and a summary of the prospectus will be available at the Company's website www.recsilicon.com. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: email@example.com Nils O. Kjerstad IR Contact Phone: +47 9135 6659 Email: firstname.lastname@example.org About the Company: REC Silicon is a leading producer of advanced silicon materials, delivering high-purity polysilicon and silicon gas to the solar and electronics industries wor
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD4.12.2020 18:30:00 CET | Press release
Results of REACH3trial also demonstratesignificant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threateningcomplication ofstem cell transplants and half of patients become steroid refractory/dependent2,3Findingsfrom the study were presented at ASH 2020,and complement previouslyreported positive results for Jakavi in acute GvHD; data to be submitted to ex-U.S. health authorities4 Basel, December4, 2020 — Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi® (ruxolitinib) significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory/dependent chronic graft-versus-host disease (GvHD) compared to best available therapy (BAT)1. The results of REACH3, the first successful, randomized Phase III trial in chronic GvHD, were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition (ASH). REACH3 is jointly sponsored by N
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-10BondsDANSKE HYPOTEK AB: 2312. SE0011116474. 2023-12-20 LANSFORSAKRINGAR HYPOTEK: 516, SE0009190390, 2023-09-20 NORDEA HYPOTEK AB: 5533, SE0010442731, 2023-09-20 SKANDINAVISKA ENSKILDA: 576, SE0010049841, 2023-12-20 SWEDISH COVERED BOND: 144., SE0011167428, 2023-06-21 STADSHYPOTEK AB: 1588, SE0011063015, 2024-03-01 SWEDBANK HYPOTEK AB: 193, SE0011089622, 2023-12-20 Bid date2020-12-10Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2312: 300 mln SEK +/-150 mln SEK 516: 600 mln SEK +/-300 mln SEK 5533: 1000 mln SEK +/-500 mln SEK 576: 800 mln SEK +/-400 mln SEK 144.: 600 mln SEK +/-300 mln SEK 1588: 1200 mln SEK +/-600 mln SEK 193: 1000 mln SEK +/-500 mln SEK Maximum 5500 mln in totalHighest permitted bid volume (corresponding nominal amount)2312: 300 mln SEK per bid 516: 600 mln SEK per bid 5533: 1000 mln SEK per bid 576: 800 mln SEK per bid 144.: 600 mln SEK per bid 1588: 1200 mln SEK per bid 193: 1000 mln SEK per bid
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-08BondsKOMMUNINVEST I SVERIGE: 2311. SE0010948240. 2023-11-13 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2020-12-08Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2311: 1000 mln SEK +/-250 mln SEK 2611: 1000 mln SEK +/-250 mln SEK Maximum 2000 mln in totalHighest permitted bid volume (corresponding nominal amount)2311: 1000 mln SEK per bid 2611: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 11.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-10Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-11BondsSWEDISH GOVERNMENT: 1060. SE0009496367. 2028-05-12 SWEDISH GOVERNMENT: 1062, SE0013935319, 2031-05-12 Bid date2020-12-11Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1060: 1500 mln SEK +/-250 mln SEK 1062: 1500 mln SEK +/-250 mln SEK Maximum 3000 mln in totalHighest permitted bid volume (corresponding nominal amount)1060: 1500 mln SEK per bid 1062: 1500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-15Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2020-12-04 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Com
Klövern offentliggör preliminärt utfall i företrädesemission4.12.2020 16:00:00 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, HONGKONG, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN ÅTGÄRD INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA LAGAR OCH FÖRESKRIFTER. YTTERLIGARE RESTRIKTIONER ÄR TILLÄMPLIGA. SE AVSNITTET ”VIKTIG INFORMATION” I SLUTET AV DETTA PRESSMEDDELANDE. Teckningsperioden i Klövern AB:s (publ) (”Klövern” eller ”Bolaget”) företrädesemission avslutades den 3 december 2020. Det preliminära utfallet visar att företrädesemissionen är övertecknad. Genom företrädesemissionen kommer Klövern att tillföras cirka 2 miljarder kronor före emissionskostnader. Det preliminära utfallet visar att 17 103 861 stamaktier av serie A och 186 435 270 stamaktier av serie B tecknades med stöd av teckningsrätter, motsvarande 98,6 procent av antalet erbjudna stamaktier av serie A respektive 98,7 procent av antalet erbjudna stamaktier av serie B. Därtill har tecknings